The Aetna and Humana tie-up promises to impact consumers, hospitals and doctors as the companies look for ways to cut costs.» Read More
Millions of people could suffer if the Supreme Court strikes down Obamacare subsidies, two doctors tell CNBC.
CNBC's Meg Tirrell, and Pascal Soriot, AstraZeneca executive director & CEO, discuss the promising results in using immunotherapy to treat all kinds of cancers.
The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.
The health-care sector is hot, and investors don't have to bet on the riskiest biotech stocks to profit.
A campaign accuses the FDA of gender bias for approving drugs to help men have sex, but none for women. The NYT reports.
Giovanni Caforio, Bristol-Myers Squibb CEO, joins CNBC's Meg Tirrell to discuss data in lung cancer and the importance of valuable medicines becoming available to patients.
Pfizer CEO Ian Read, discusses the PALOMA-3 trial for its oncology treatment Ibrance to treat breast cancer, drug pricing and competition in the pharmaceutical industry.
CNBC's Meg Tirrell, and Daniel O'Day, Roche Pharmaceuticals COO, talk about the the encouraging results in treating lung cancer and using precision medicines to personalize treatment.
CNBC's Meg Tirrell has the update on the latest development from this year's American Society of Clinical Oncology meeting.
Bristol-Myers Squibb's battering after a disappointing drug trial serves as a buying opportunity, "Fast Money" traders said.
A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.
Texas is forgoing about $100 billion in federal funds by not expanding a major health program for the poor.
It's that time again. With researchers set to convene at the American Society of Clinical Oncology meeting, here are the stocks to watch.
Meg Tirrell tells us why the future of cancer therapy may almost be here.
Incyte stands to benefit from unveiling data on its cancer treatments at a conference in the coming days, a biotech analyst said.
Health insurer Humana has received takeover interest, with potential bidders including Aetna and Cigna, according to reports.
As the government program reaches the half-century mark, it needs to get into the digital age, says this University of Rochester professor.
Congressional Republicans have yet to act on plans to deal with the potential loss of subsidies for HealthCare.gov customers.
Pfizer reportedly approached Cellectis with a deal that could value it at about $1.64 billion, the Financial Times reported.
Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.
Get the best of CNBC in your inbox